Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors

JAMA

Volumn 307, Issue 12, 2012, Pages 1312-1314

  Blanke, Charles D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; DRUG WITHDRAWAL; EDITORIAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; FEMALE; GASTROINTESTINAL TUMOR; MALE; NOTE;

ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; PIPERAZINES; PYRIMIDINES;

EID: 84859186912     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.368     Document Type: Editorial

References (15)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
2. Winton T, Livingston R, Johnson D, et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589-2597.
3. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15(1):246-250. (Pubitemid 27020580)
4. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472-480. (Pubitemid 34879334)
5. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626-632. (Pubitemid 351264358)
6. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-58. (Pubitemid 30043939)
7. Dematteo RP, Ballman KV, Antonescu CR, et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9669):1097-1104.
8. FDA approves Gleevec (imatinib mesylate) to prevent recurrence of rare gastrointestinal cancer [news release]. US Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116997.htm. Accessed February 2, 2012.
9. Joensuu H, Eriksson M, Hall KS, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307(12):1265-1272.
10. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411-1419.
11. Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045-1052.
12. Ray-Coquard IL, Bui BN, Adenis A, et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR-14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: a French Sarcoma Group Study [abstract 10032]. J Clin Oncol. 2010;28:706s.
13. Belfiglio M, Valentini M, Pellegrini F, et al; Interdisciplinary Group for Cancer Care Evaluated (GIVIO) Group. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer. 2005;104(11):2334- 2339. (Pubitemid 41691553)
14. Bolla M, de Reijke TM, Van Tienhoven G, et al; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516-2527.
15. Imatinib mesylate tablets. US Food and Drug Administration. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm289789.htm. Accessed February 2, 2012.